APA

Dispenzieri A., Tong C., LaPlant B., Lacy M. Q., Laumann K., Dingli D., Zhou Y., Federspiel M. J., Gertz M. A., Hayman S., Buadi F., O'Connor M., Lowe V. J., Peng K. & Russell S. J. (20171215). Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. : Leukemia.

Chicago

Dispenzieri A, Tong C, LaPlant B, Lacy M Q, Laumann K, Dingli D, Zhou Y, Federspiel M J, Gertz M A, Hayman S, Buadi F, O'Connor M, Lowe V J, Peng K-W and Russell S J. 20171215. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. : Leukemia.

Harvard

Dispenzieri A., Tong C., LaPlant B., Lacy M. Q., Laumann K., Dingli D., Zhou Y., Federspiel M. J., Gertz M. A., Hayman S., Buadi F., O'Connor M., Lowe V. J., Peng K. and Russell S. J. (20171215). Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. : Leukemia.

MLA

Dispenzieri A, Tong C, LaPlant B, Lacy M Q, Laumann K, Dingli D, Zhou Y, Federspiel M J, Gertz M A, Hayman S, Buadi F, O'Connor M, Lowe V J, Peng K-W and Russell S J. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. : Leukemia. 20171215.